EP 1465998 A2 20041013 - SINGLE NUCLEOTIDE POLYMORPHISMS PREDICTING CARDIOVASCULAR DISEASE AND MEDICATION EFFICACY
Title (en)
SINGLE NUCLEOTIDE POLYMORPHISMS PREDICTING CARDIOVASCULAR DISEASE AND MEDICATION EFFICACY
Title (de)
HERZ-KREISLAUF-ERKRANKUNG UND MEDIKAMENTENWIRKUNG VORAUSSAGENDE EINZELNUKLEOTID-POLYMORPHISMEN
Title (fr)
POLYMORPHISMES MONONUCLEOTIDIQUES SERVANT A PREDIRE UNE MALADIE CARDIOVASCULAIRE ET L'EFFICACITE DE MEDICAMENTS
Publication
Application
Priority
- EP 03729224 A 20030107
- EP 0300060 W 20030107
- EP 02000153 A 20020108
Abstract (en)
[origin: WO03057911A2] The present invention relates to isolated polynucleotides encoding a cardiovascular associated (CA) gene polypeptide useful in methods to identify therapeutic agents and useful for preparation of a medicament to treat cardiovascular disease, the polynucleotide is selected from the group comprising:SEQ ID 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94 with allelic variation as indicated in the sequences section contained in a functional surrounding like full length cDNA for CA gene polypeptide and with or without the CA gene promoter sequence.The invention also provides diagnostic methods and kits including antibodies determining whether a human subject is at risk for a cardiovascular disease. The invention provides further polymorphic sequences and other genes.
IPC 1-7
C12N 15/12; C07K 14/47; C12Q 1/68; G01N 33/68; A61K 31/713; A61P 9/00
IPC 8 full level
G01N 33/50 (2006.01); A61K 31/713 (2006.01); A61K 35/12 (2015.01); A61K 35/74 (2015.01); A61K 45/00 (2006.01); A61P 9/00 (2006.01); A61P 9/08 (2006.01); A61P 9/10 (2006.01); A61P 9/12 (2006.01); C07K 14/47 (2006.01); C12N 1/15 (2006.01); C12N 1/19 (2006.01); C12N 1/21 (2006.01); C12N 5/10 (2006.01); C12N 15/09 (2006.01); C12N 15/12 (2006.01); C12P 21/02 (2006.01); C12Q 1/02 (2006.01); C12Q 1/68 (2006.01); C12Q 1/6883 (2018.01); G01N 33/15 (2006.01); G01N 33/53 (2006.01); G01N 33/566 (2006.01); G01N 33/68 (2006.01); A61K 38/00 (2006.01)
CPC (source: EP)
A61P 9/00 (2018.01); A61P 9/08 (2018.01); A61P 9/10 (2018.01); A61P 9/12 (2018.01); C07K 14/705 (2013.01); C12Q 1/6883 (2013.01); A61K 38/00 (2013.01); C12Q 2600/156 (2013.01)
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR
DOCDB simple family (publication)
WO 03057911 A2 20030717; WO 03057911 A3 20031218; AU 2003201159 A1 20030724; AU 2003201159 A8 20030724; EP 1465998 A2 20041013; EP 1978108 A2 20081008; EP 1978108 A3 20090107; JP 2004154120 A 20040603
DOCDB simple family (application)
EP 0300060 W 20030107; AU 2003201159 A 20030107; EP 03729224 A 20030107; EP 08006507 A 20030107; JP 2003002091 A 20030108